Episode IV: Mike Zack, PGxAI
Episode 4, Oct 25, 02:39 PM
Tomas and Evgeny sit down with Dr. Mike Zack, CEO of PGxAI, to discuss the journey of building a global med-tech unicorn in precision medicine. Dr. Zack, a leading expert in pharmacogenomics with a substantial research background, shares insights on scaling innovations in the healthcare space.
In their fourth epizode, Venture Vitals’ Tomas Studenik and Evgeny Shvarov invited a precision medicine startup CEO, Mike, to be their guest and respondent for over 45 minutes of all-about-building-a-global-med-tech-unicorn. Mike Zack, MD, PhD, MPH, is the Co-Founder and CEO of PGxAI (https://pgx.ai), a key opinion leader (KOL) in pharmacogenomics with an H-index of 40 and >40K citations. Mike is a member of major pharmacogenomics consortiums, including CPIC and PGRN, and has published in top-tier journals such as Nature Pharmacogenomics Journal, The Lancet, and others. Mike is supported by his co-founder and investor Allan Gobbs, who has successfully exited nine companies, and Russ Altman, a Stanford professor, serial entrepreneur, and world-leading KOL in multi-omics.
PGX.ai is a Caelestinus Health Tech Incubator alumnus.
PGX.ai is a Caelestinus Health Tech Incubator alumnus.